{"filing":{"accession_number":"0001193125-26-281200","cik":"0001810560","ticker":"REVBW","company_name":"REVELATION BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"revb-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526281200/revb-20260624.htm"},"events":[{"id":13566,"run_id":12055,"accession_number":"0001193125-26-281200","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Company amended and restated executive employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III, effective June 24, 2026, increasing change-in-control severance benefits to 2x base salary plus target bonus with COBRA reimbursement up to 18 months, expanding flexibility for outside activities, and establishing a three-year initial term with automatic renewal.","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10739,"accession_number":"0001193125-26-281200","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on amended and restated executive employment agreements for the CEO (James Rolke) and CFO (Chester S. Zygmont, III) effective June 24, 2026. The material changes include: (i) increased change-in-control severance benefits (2x base salary plus target bonus, plus COBRA reimbursement up to 18 months), (ii) expanded flexibility for outside activities, and (iii) a three-year initial term with automatic renewal. These are compensatory arrangements—specifically severance modifications and employment term changes—that would materially affect investor assessment of executive compensation obligations and change-of-control costs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13567,"run_id":12055,"accession_number":"0001193125-26-281200","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"summary":"The Company amended its Second Amended and Restated Bylaws to add provisions on universal proxy rules compliance, formally define 'Cause' for director and officer removal, establish officer removal procedures, and implement emergency CEO/CFO succession protocols.","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10740,"accession_number":"0001193125-26-281200","item_number":"5.03","item_title":"Amendments to Certificate of Incorporation or Bylaws.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure concerns amendments to the Company's Second Amended and Restated Bylaws, including new provisions on universal proxy rules compliance, formal definition of \"Cause\" for director and officer removal, officer removal procedures, and emergency CEO/CFO succession. These are routine governance and administrative matters that clarify procedural rules and governance structures but do not involve material changes to the registrant's business, financial condition, or strategic direction. While governance-related, the amendments are standard corporate governance housekeeping and do not rise to materiality for a reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13568,"run_id":12055,"accession_number":"0001193125-26-281200","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"At the Annual Meeting of Stockholders held on June 24, 2026, stockholders approved three proposals: election of Jennifer Carver as a Class A director, authorization of reverse stock splits in a range of one-for-two to one-for-250, and ratification of Baker Tilly US, LLP as independent auditor.","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10741,"accession_number":"0001193125-26-281200","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders held on June 24, 2026. The filing presents voting results for three proposals: election of Jennifer Carver as a Class A director, authorization of reverse stock splits (one-for-two to one-for-250 ratio), and ratification of Baker Tilly US, LLP as independent auditor. All three proposals passed. The disclosure of shareholder vote results is material to investors as it confirms governance actions and strategic decisions (including the reverse split authorization) approved by the stockholder base.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10739,"accession_number":"0001193125-26-281200","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on amended and restated executive employment agreements for the CEO (James Rolke) and CFO (Chester S. Zygmont, III) effective June 24, 2026. The material changes include: (i) increased change-in-control severance benefits (2x base salary plus target bonus, plus COBRA reimbursement up to 18 months), (ii) expanded flexibility for outside activities, and (iii) a three-year initial term with automatic renewal. These are compensatory arrangements—specifically severance modifications and employment term changes—that would materially affect investor assessment of executive compensation obligations and change-of-control costs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24"},{"id":10740,"accession_number":"0001193125-26-281200","item_number":"5.03","item_title":"Amendments to Certificate of Incorporation or Bylaws.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure concerns amendments to the Company's Second Amended and Restated Bylaws, including new provisions on universal proxy rules compliance, formal definition of \"Cause\" for director and officer removal, officer removal procedures, and emergency CEO/CFO succession. These are routine governance and administrative matters that clarify procedural rules and governance structures but do not involve material changes to the registrant's business, financial condition, or strategic direction. While governance-related, the amendments are standard corporate governance housekeeping and do not rise to materiality for a reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24"},{"id":10741,"accession_number":"0001193125-26-281200","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders held on June 24, 2026. The filing presents voting results for three proposals: election of Jennifer Carver as a Class A director, authorization of reverse stock splits (one-for-two to one-for-250 ratio), and ratification of Baker Tilly US, LLP as independent auditor. All three proposals passed. The disclosure of shareholder vote results is material to investors as it confirms governance actions and strategic decisions (including the reverse split authorization) approved by the stockholder base.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:48:58.471067+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-06-24"}]}